Showing results (211-220 of 258) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 1, 2021
Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability-High/Mismatch Repair-Deficient TumorsAntoine Hollebecque, Hyun C Chung, Maria J de Miguel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.
Scientific Reports|April 23, 2020
Impact of cooking oil fume exposure and fume extractor use on lung cancer risk in non-smoking Han Chinese womenTzu-Yu Chen, Yao-Hwei Fang, Hui-Ling Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.
Journal for Immunotherapy of Cancer|January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyPaolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Cancer Discovery|October 20, 2022
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTONRyan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, et al.
Pageof 26